ARTICLE | Finance
Invoking Sophia
Invoke providing more than cash to scale Sophia's whole genome sequence analysis
July 14, 2014 7:00 AM UTC
Sophia Genetics S.A. expects to tap into multiple assets from Invoke Capital, the lead investor in the bioinformatics company's $13.8 million series B round. In addition to the cash, Sophia will work with mathematicians at another Invoke portfolio company to improve its algorithms.
Sophia was founded in 2011 to develop analysis software for genome sequencing data. The company already is selling its NGS Dry Lab Service bioinformatics platform in six European countries. The platform analyzes and stores raw sequencing files generated by next-generation sequencing (NGS) technologies, and includes visualization and analysis tools. CEO Jurgi Camblong told BioCentury that Sophia is focused on genome analysis for cancer...